S. 148 · 118th Congress (2023–2025)
Stop STALLING Act
This bill makes it an unfair method of competition to submit an objectively baseless petition to the Food and Drug Administration (FDA) in an attempt to interfere with a competitor's application for market approval of a drug.
The bill authorizes the Federal Trade Commission to sue an individual or entity that submits such a petition to the FDA. A party found liable in such a lawsuit shall be subject to civil penalties, such as a fine of up to $50,000 for each day that the FDA spent reviewing the baseless petition.
Show official title
A bill to enable the Federal Trade Commission to deter filing of sham citizen petitions to cover an attempt to interfere with approval of a competing generic drug or biosimilar, to foster competition, and facilitate the efficient review of petitions filed in good faith to raise legitimate public health concerns, and for other purposes.
Expired in Senate committee
Derived from the legislative history, not an official disposition.
Latest actionReported by committee
This bill’s path
This is S. 148’s recorded path, not a universal congressional workflow.
How bills become lawAll actionsIntroduced
Passed Senate
Passed House
Sent to President
Signed into law
Expired
- Sponsor
- Sen. Amy Klobuchar (D-MN)
- Cosponsors
8 cosponsors
6 original · 2 later
3 R · 5 D
- Sen. Richard Blumenthal (D-CT)· Original · Jan 30, 2023
- Sen. Cory A. Booker (D-NJ)· Original · Jan 30, 2023
- Sen. Mike Braun (R-IN)· Original · Jan 30, 2023
- Sen. Ted Cruz (R-TX)· Original · Jan 30, 2023
- Sen. Richard J. Durbin (D-IL)· Original · Jan 30, 2023
- Sen. Chuck Grassley (R-IA)· Original · Jan 30, 2023
- Sen. Jon Ossoff (D-GA)· Later · Feb 1, 2023
- Sen. Peter Welch (D-VT)· Later · Feb 9, 2023
- Policy area
- Health
- Subjects
- Administrative remedies
- Business ethics
- Civil actions and liability
- Competition and antitrust
- Department of Health and Human Services
- Drug safety, medical device, and laboratory regulation
- Food and Drug Administration (FDA)
- Licensing and registrations
2 more
- Prescription drugs
- Public participation and lobbying
On this page
Timeline
i
In chronological order. Major procedural acts are shown in full. Committee work and ordinary amendments fold in place where they happened, so they do not jump the sequence or stretch the timeline.
Introduced in Senate
Document: Introduced in Senate
Sources
- Congress.gov action
- Library of Congress
- Latest
▸ 3 committee actions · Jan 30, 2023 – Mar 1, 2023
Referred to committee
Read twice and referred to the Committee on the Judiciary.
Sources
- Congress.gov action
- Senate
Ordered reported
Committee on the Judiciary. Ordered to be reported with an amendment in the nature of a substitute favorably.
Sources
- Congress.gov action
- Senate
Reported by committee
Committee on the Judiciary. Reported by Senator Durbin with an amendment in the nature of a substitute. Without written report.
Sources
- Congress.gov action
- Senate
Expired
Introduced → Reported by committee → No further action before the 118th Congress ended.
Committees
Feb 9, 2023 · Meeting
Text & titles
i
Each distinct name Congress.gov recorded, once. Official, short, display, and popular titles stay distinct when the wording differs. The same wording is not repeated for every text version.
Titles (3)
Stop STALLING Act
Display title, Short title · Introduced in Senate, Reported to Senate
Stop Significant and Time-wasting Abuse Limiting Legitimate Innovation of New Generics Act
Short title · Introduced in Senate, Reported to Senate
A bill to enable the Federal Trade Commission to deter filing of sham citizen petitions to cover an attempt to interfere with approval of a competing generic drug or biosimilar, to foster competition, and facilitate the efficient review of petitions filed in good faith to raise legitimate public health concerns, and for other purposes.
Official title · Introduced in Senate